SCHEMBL5651844

SCHEMBL5651844

COc1cc(C(=O)NN2CCCCC2)ccc1-c1nc2ncccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.56
PDE5A O76074 10/20 0.54
LMNA P02545 2/20 0.54
KDM4E B2RXH2 1/20 0.54
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54
CYP1A2 P05177 1/20 0.54
HPGD P15428 1/20 0.54
KMT2A Q03164 1/20 0.54
PDE3B Q13370 1/20 0.54
PDE3A Q14432 1/20 0.54
HSD17B10 Q99714 1/20 0.54
AURKA O14965 2/20 0.52
MAPT P10636 2/20 0.44
POLB P06746 1/20 0.44
ATM Q13315 1/20 0.44
PDE4A P27815 3/20 0.43
PDE4B Q07343 3/20 0.43
PDE4C Q08493 3/20 0.43
PDE4D Q08499 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652807 0.91 PDE5A (0.53) PDE2APDE5ALMNAKDM4EMEN1
SCHEMBL5653824 0.88 AURKA (0.45) PDE2APDE5ALMNAKDM4EMEN1
SCHEMBL5650901 0.86 AURKA (0.45) PDE2APDE5ALMNAKDM4EMEN1
SCHEMBL5653967 0.86 AURKA (0.45) PDE2APDE5ALMNAKDM4EMEN1
SCHEMBL5650016 0.85 MGAM (0.48) KDM4EMAPTPDE4APDE4BPDE4C
SCHEMBL10746239 0.84 PDE2A (0.65) PDE2APDE5ALMNAKDM4EMEN1
SCHEMBL5653237 0.82 HDAC6 (0.46) MEN1CYP1A2HPGDKMT2AMAPT
SCHEMBL5651444 0.81 PRMT5 (0.59) AURKAPRMT5
Hydrochloric Acid SCHEMBL10747569 0.81 PDE2A (0.66) PDE2APDE5ALMNAKDM4EMEN1
SCHEMBL10742290 0.81 PDE2A (0.69) PDE2APDE5ALMNAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 PDE2A 2744/4885PDE5A 3793/4885LMNA 4376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.